Hypericin-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEHypericinCat.No.:HY-N0453CASNo.:548-04-9分?式:C??H??O?分?量:504.44作?靶點:Apoptosis;InfluenzaVirus;Antibiotic;MonoamineOxidase;

PKC;CytochromeP450;Dopamineβ-hydroxylase;Reverse

Transcriptase;Telomerase作?通路:Apoptosis;Anti-infection;NeuronalSignaling;Epigenetics;

TGF-beta/Smad;MetabolicEnzyme/Protease;CellCycle/DNA

Damage儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:250mg/mL(495.60mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.9824mL9.9120mL19.8240mL5mM0.3965mL1.9824mL3.9648mL10mM0.1982mL0.9912mL1.9824mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:2.08mg/mL(4.12mM);Suspendedsolution;Needultrasonic2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.08mg/mL(4.12mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Hypericin?種天然存在于貫葉連翹中的物質(zhì)。HypericinPKC(蛋?激酶C)、MAO(單胺氧化酶)、多巴胺-beta-羥化酶、逆轉(zhuǎn)錄酶、端粒酶和CYP(cytochromeP450)的抑制劑。Hypericin具有抗腫瘤、抗病毒和抗抑郁的活性，可誘導(dǎo)細胞凋亡。體外研究Hypericin(0.25-4μM;24h)inhibitsthegrowthoffibroblasts(Fb),melanocytes(Mc),andkeratinocytes(Kc)[2].Hypericin(3μM;24h)treatmentcaninducecellsapoptosis[2].CellViabilityAssay[2]CellLine:Fibroblasts(Fb),melanocytes(Mc),andkeratinocytes(Kc)Concentration:0.25μM;0.5μM;1μM;2μM;3μM;4μMIncubationTime:24hoursResult:ShowedtheLD50forFbandMcat1.75μMand3.5μM,respectively,andforKcatagreaterdosethan4μM.ApoptosisAnalysis[2]CellLine:Fibroblasts(Fb),melanocytes(Mc),andkeratinocytes(Kc)Concentration:3μMIncubationTime:24hoursResult:Showedasignificant(p<0.001)earlyapoptoticFbpopulation(64%),andasmaller,significant(p<0.05)earlyapoptoticMcpopulation(20%).體內(nèi)研究Hypericin(Intravenousinjection;10mg/kg;once)treatmentdelaystumorgrowth[3].AnimalModel:18-20week-oldfemaleBALB/cmiceinjectedwithCT26carcinomas[3]Dosage:10mg/kgAdministration:Intravenousinjection;10mg/kg;onceResult:Showedafourtimesdelayedtumorgrowthcomparedtothecontrolgroups.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE戶使?本產(chǎn)品發(fā)表的科研?獻?Cancers(Basel).2022Mar19;14(6):1575.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].AKubin,etal.Hypericin--thefactsaboutacontroversialagent.CurrPharmDes.2005;11(2):233-53.[2].APopovic,etal.DifferentialsusceptibilityofprimaryculturedhumanskincellstohypericinPDTinaninvitromodel.JPhotochemPhotobiolB.2015Aug;149:249-56.[3].RenataSanovic,etal.Lowdosehypericin-PDTinducescompletetumorregressioninBALB/cmicebearingCT26coloncarcinoma.PhotodiagnosisPhotodynTher.2011Dec;8(4):291-6.McePdfHeightCaution:Producthasnotbeenfullyv